Superbug symptoms under attack

Life sciences business OptiBiotix has filed a patent for a product which combats infections caused by superbugs such as MRSA. York-based OptiBiotix Health, which develops compounds to tackly obesity, high cholesterol and diabetes, has developed microbial proteins to fight superbug infections (also known as Health Care Acquired Infections or HCAIs). HCAIs lead to higher morbidity and mortality, and cost the NHS an estimated £1bn per year.

Stephen O’Hara, CEO of OptiBiotix, said: “These proteins prevent skin damage, stop pathogenic bacteria from growing, and most importantly prevent it from reattaching, reducing the risk of reinfection with AMR superbugs.”

See the article in full at

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.